Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | MDM2 | Q00987 | 7/20 | 0.53 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3728174 | 1.00 | MDM4 (0.56) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL3728179 | 1.00 | MDM4 (0.56) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL29401227 | 0.88 | MDM4 (0.56) | MDM4TP53MDM2CASP3 | |
| SCHEMBL29368221 | 0.88 | MDM4 (0.56) | MDM4TP53MDM2CASP3 | |
| SCHEMBL1486207 | 0.88 | MDM4 (0.56) | MDM4TP53MDM2CASP3 | |
| SCHEMBL29400706 | 0.85 | MDM4 (0.54) | MDM4TP53MDM2CASP3 | |
| SCHEMBL30234099 | 0.85 | MDM4 (0.54) | MDM4TP53MDM2CASP3 | |
| SCHEMBL5717688 | 0.85 | MDM4 (0.54) | MDM4TP53MDM2CASP3 | |
| SCHEMBL29589719 | 0.85 | MDM4 (0.54) | MDM4TP53MDM2CASP3 | |
| SCHEMBL27582559 | 0.85 | MDM4 (0.54) | MDM4TP53MDM2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114634554-B | Anti-wrinkle cyclic hexapeptide compound and preparation method thereof | 浙江湃肽生物股份有限公司 | 2022-12-06 | — | — | CN | claimed |
| CN-114634554-A | Anti-wrinkle cyclic hexapeptide compound and preparation method thereof | 浙江湃肽生物股份有限公司 | 2022-06-17 | — | — | CN | claimed |
| US-20260053885-A1 | PHARMACEUTICAL COMPOSITIONS | RHYTHM PHARMACEUTICALS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2026-01-22 | — | — | US | disclosed |
| EP-3966226-B1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2025-08-07 | — | — | US | disclosed |
| US-20250188124-A1 | PEPTIDE COMPOSITIONS | RHYTHM PHARMACEUTICALS, INC. | 2025-06-12 | — | — | US | disclosed |
| US-20250163104-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2025-05-22 | — | — | US | disclosed |
| US-12285460-B2 | Pharmaceutical compositions | RHYTHM PHARMACEUTICALS, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| EP-4526323-A1 | MACROCYCLIC IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2025-03-26 | — | — | EP | disclosed |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-18 | — | — | US | disclosed |
| WO-2024059472-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023225661-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-23 | — | — | WO | disclosed |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-06 | — | — | US | disclosed |
| CN-115957297-A | Pharmaceutical composition | 节奏制药公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-115957296-A | Pharmaceutical composition | 节奏制药公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-114634554-B | Anti-wrinkle cyclic hexapeptide compound and preparation method thereof | 浙江湃肽生物股份有限公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-114634554-A | Anti-wrinkle cyclic hexapeptide compound and preparation method thereof | 浙江湃肽生物股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
| US-20220160818-A1 | PHARMACEUTICAL COMPOSITIONS | RHYTHM PHARMACEUTICALS, INC. | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503491-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | MDM4 2629/4885TP53 2648/4885MDM2 1513/4885 |
| US-20220160818-A1 | PHARMACEUTICAL COMPOSITIONS | PCTP, SLC27A1, CETP | MDM4 4126/4885TP53 3123/4885MDM2 4473/4885 |
| US-20250163104-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | MDM4 1009/4885TP53 127/4885MDM2 856/4885 |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | MDM4 3040/4885TP53 421/4885MDM2 2477/4885 |
| US-11667675-B2 | MASP inhibitory compounds and uses thereof | MASP2, SERPINB1, SPINT2 | MDM4 2629/4885TP53 2648/4885MDM2 1513/4885 |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | MDM4 1128/4885TP53 158/4885MDM2 757/4885 |
| US-12285460-B2 | Pharmaceutical compositions | PCTP, SLC27A1, CETP | MDM4 4126/4885TP53 3123/4885MDM2 4473/4885 |
| US-20250188124-A1 | PEPTIDE COMPOSITIONS | MC4R, MC3R, MC5R | MDM4 3305/4885TP53 4014/4885MDM2 4745/4885 |
| US-20240124522-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SERPINB1, SPINT2 | MDM4 2629/4885TP53 2648/4885MDM2 1513/4885 |
| US-20260053885-A1 | PHARMACEUTICAL COMPOSITIONS | ARGLU1, FFAR3, ASNS | MDM4 3099/4885TP53 3078/4885MDM2 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.